New Federal Contractors — August 09, 2026
The three contracts total $993.8 million, with one-third defense-related (the VA award to QTC Medical Services/Leidos) and the remainder civilian HHS awards. The dominant theme is biodefense and health services: SIGA Technologies' $626.5 million smallpox antiviral contract from HHS/BARDA is the highest-conviction signal, offering long-term revenue visibility through 2029 under a fixed-price structure. However, execution risk is medium given the fixed-price nature, and the contract's full-and-open competition suggests potential future competition. The VA medical exam contract for Leidos is a completed, one-year award with no forward growth visibility, while the OUR RESCUE legal services contract carries high pricing risk due to its time-and-materials structure and short base period. Key watch items include SIGA's cost performance and option exercises, and HHS's decision on OUR RESCUE's options by February 2027.